



- (51) **International Patent Classification:**
C12N 15/113 (2010.01) C12N 9/02 (2006.01)
- (21) **International Application Number:**
PCT/US2021/072370
- (22) **International Filing Date:**
12 November 2021 (12.11.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/113,689 13 November 2020 (13.11.2020) US
- (71) **Applicant: DICERNA PHARMACEUTICALS, INC.**
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts 02421 (US).
- (72) **Inventors: BROWN, Bob Dale;** c/o Dicerna Pharmaceuticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts 02421 (US). **DUDEK, Henryk T.;** c/o Dicerna Pharmaceuticals, Inc., 75 Hayden Avenue, LEXINGTON, Massachusetts 02421 (US). **SAXENA, Utsav;** c/o Dicerna Pharmaceuticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts 02421 (US).
- (74) **Agent: REID, Andrea L.C.** et al.; One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** CHEMICAL MODIFICATIONS FOR INHIBITING EXPRESSION OF ALDH2

DP11663P:DP16281G




FIG. 3

(57) **Abstract:** This disclosure relates to chemically modified oligonucleotides, compositions, and methods useful for reducing ALDH2 expression, to treat alcoholism. Disclosed oligonucleotide for the reduction of ALDH2 expression is modified for enhanced pharmacological properties.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*